Building a Virtually Integrated Life Sciences Company

Saturday, December 6, 2008

The traditional business model dominating the pharmaceutical industry for over 100 years is rapidly eroding under new drivers for innovation and increasing financial pressures. Big Pharma as an integrated business from basic scientific research all the way through to marketing, manufacturing, and distribution is rapidly changing as more biotechnology innovation is coming straight from the laboratories of universities and independent research institutions. Smaller companies, often startups, are also using technologies developed at non-profit institutions to develop new lead compounds, new manufacturing methodologies, and new drug delivery vehicles, rather than invest in their own in-house early stage research.
Financing, too, can be a serious challenge. The almost total absence of an initial public offering market requires that venture capital firms reserve money for later rounds and require companies in which they do invest to make that money last much longer than before. Accordingly, today’s biotech companies need to build a company around their core strengths and forge relationships with other businesses that provide complementary goods and services in order to conserve resources. The result is no longer the Fully Integrated Pharmaceutical Company, but really more of a Virtually Integrated Pharmaceutical Company. Moreover, this model is being used, not just for pharmaceuticals, but for a wide variety of life science products and services, including diagnostics and devices.
The December 6, 2008 session of the Caltech/MIT Enterprise Forum will focus on the new business model for the biotechnology entrepreneur. What is the essential core of a life sciences business? What parts of the business can be delegated to others? How, and when, does the fledgling company develop relationships with other companies with complementary strengths? What are the nature of the relationships between new companies and the large life sciences companies? Which relationships are advantageous and which are potentially dangerous? Even more important, who invests in these virtual companies and what criteria are they using?
Our panel of speakers will include representatives of two different kinds of research institution, a contract manufacturers, a clinical research organization, a pharmaceutical company, and the venture capital community.

Saturday morning, December 6, 2008
Registration and Continental Breakfast: 8:00 a.m. at Baxter Hall, Caltech
Program: 9:00 a.m. to 11:30 a.m. at Baxter Lecture Hall
Networking: 11:30 a.m. – 12:00 noon at Baxter Hall, Caltech
Directions/Maps: Directions to the Forum; Caltech’s Interactive Map


Here is the link to our Yellow pages ad

new radio spots on managed services

response to our managed services ad has been slower compared to our earlier spots. Ads were playing all week 8th minute of the most hours –

Here is the second set of ads running on CBS KFWB through the end of this week. Response has been good. We are receiving calls from as far as Texas. We have a brand new ad starting next week.

The OC 360 radio ads

Here it is! The first set of ads will start running on CBS KFWB 980 beginning Monday, September 24

new marketing initiatives

Beginning 19 September, people in Santa Monica and West side will have local numbers to get in touch with The OC 360. The #s will be used to track the demographics of the calls. The OC 360 is collaborating with United Yellow Pages. The OC 360 ads will also appear in their books for 9 months.



We are looking forward to starting the advertising campaign on CBS 980 beginning this month. I am working with Joe at the station to finalize the scripts.

Also, thanks to Chris Consorte, Cliff Allen, Bruce Grey, Dr. Richard Savich – They have been great with their feedback on our business plan.